Skip to main content

Table 3 Association of age with non-prescription of ACT among mRDT-positive patients

From: Patients with positive malaria tests not given artemisinin-based combination therapies: a research synthesis describing under-prescription of antimalarial medicines in Africa

Project siteAge (years)Total number (%) of mRDT-positive patients not prescribed ACT by age*UnadjustedAdjusted
OR95% CIp valueOR95% CIp value
Cam1< 527/94 (28.7)1.00Ref.0.1121.00Ref.0.089
≥ 535/166 (21.1)0.660.40, 1.100.640.38, 1.07
Ghan1< 515/406 (3.7)1.00Ref.< 0.0011.00Ref.< 0.001
≥ 514/899 (1.6)0.410.30, 0.570.410.30, 0.57
Nige1< 516/42 (38.1)1.00Ref.0.2181.00Ref.0.618
≥ 5141/493 (28.6)0.650.33, 1.290.850.46, 1.59
Tanz1< 564/153 (41.8)1.00Ref.0.0491.00Ref.0.077
≥ 524/84 (28.6)0.560.31, 1.000.550.28, 1.07
Tanz2< 5247/1480 (16.7)1.00Ref.< 0.0011.00Ref.< 0.001
≥ 5700/2916 (24.0)1.581.31, 1.901.421.15, 1.76
Uga1< 53015/37,287 (8.1)1.00Ref.0.0811.00Ref.0.063
≥ 52862/51,473 (5.6)0.670.43, 1.050.660.42, 1.02
Uga3< 530/2239 (1.3)1.00Ref.0.9171.00Ref.0.898
≥ 544/3358 (1.3)0.980.64, 1.500.970.63, 1.49
Uga2§< 111/242 (4.6)1.00Ref.0.0171.00Ref.0.034
≥ 146/3135 (1.5)0.310.12, 0.810.320.11, 0.92
  1. *n is number of patients per study site (and endemicity setting) not prescribed ACT among all mRDT-positive patients with complete data for age, gender, endemicity setting, sector, and intervention arm. Total number of mRDT-positive patients not prescribed ACT: N = 7291/104,454
  2. All adjusted models included age and gender as a priori variables and where sufficient data available (≥ 10 outcomes per cell), plus all other variables found significant by univariate analyses (p < 0.05). Statistical models for each site vary in composition due to differences in study designs. Final regression models for each site include the following variables: Cam1—gender and age; Ghan1—age only; Nige1—gender, age, sector, and endemicity setting; Tanz1—gender, age, and endemicity setting; Tanz2—gender, age, and endemicity setting; Uga1—gender and age; Uga2—gender, age, and endemicity setting; and Uga3—gender and age
  3. Confidence intervals and p value calculated using Wald’s test
  4. §Uga2 age categories </≥ 1 due to primary study limited to patients aged under 6 years